Abstract
Malignant pericarditis, when associated with massive pericardial effusion, presents a critical condition in lung cancer patients. Because this condition often arises in terminally ill patients, intensive therapy such as multi-drug combination chemotherapy is rarely appropriate. This study evaluated the clinical relevance of intrapericardial administration of carboplatin for controlling malignant pericardial effusions associated with non-small-cell lung carcinoma (NSCLC). The method used for 10 eligible patients consisted of draining the pericardial effusion and infusing 300 mg/body of carboplatin in 50 ml of saline through an in-place catheter into the pericardial space and clamping the catheter for 40 min. Nine of the 10 patients showed satisfactory results, and 8 experienced complete regression of the effusion. No major or minor adverse effects were observed. Pharmacokinetics analysis revealed that the concentration of free platinum in the pericardial fluid was very high while that of total platinum in the circulating plasma was very low, assuring the usefulness of the intrapericardial instillation of carboplatin in terminally ill patients for controlling malignant pericardial effusion when the systemic delivery of cytotoxic agents is inappropriate. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S, Wiltshaw E, Smith IE, Baker JM, Peckham MJ and Harrap KR (1982) Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylase platinum II. Cancer Chemother and Pharmacol 9: 140–147
Celermajor DS, Boyer M, Bailey BP and Tattersall MHN (1991) Pericardiocentesis for symptomatic malignant pleural effusions: a study of 36 patients. Med J Aust 154: 19–22
Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, Graffeo R, Zampino G, De Pas T, Cipolla G, Martinoni C and Goldhirsch A (1998) Intracavitary chemotherapy with thiopeta in malignant pericardial effusions: An active and well-tolerated regimen. JCO 16: 2371–2376
Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE and Collins JM (1983) A phase I and pharmacokinetic study of diammine-cyclobutanedicarboxylatoplatinum (NSC 241240). Cancer Res 43: 4470–4473
Davis S, Rambotti P and Grignani F (1984) Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: an analysis of thirty-three cases. J Clin Oncol 2: 631–636
Dempke W and Firusian N (1999) Treatment of malignant pericardial effusion with32P-colloid. Br J Cancer 80: 1955–1957
Fiorentino MV, Daniele O, Morandi P, Aversa SML, Ghiotto C, Paccgnella A and Fornasiero A (1988) Intrapericardial instillation of platin in malignant pericardial effusion. Cancer 62: 1904–1906
Go RS and Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. JCO 17: 409–422
Gotoh T, Fujita Y, Uchida H, Arimoto T, Sakai M, Kida T, Fujii T, Hiramori N, Iwasaki Y, Nakamura T and Nakagawa M (1991) Successful treatment with intrapericardial administration of carboplatin in a case of squamous cell lung cancer with malignant pericardial effusion. Jpn J Cancer Chemother 18: 2337–2340
Herrstedt J, Clementsen P and Hansen P (1992) Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer 28A: 1070–1073
Kitamura S, Wagai F, Izumi T, Sugiyama Y and Kosaka K (1981) Treatment of carcinomatous pericarditis with doxycycline: intrapericardial doxycycline for control of malignant pericardial effusion. Curr Therapeut Res 30: 589–596
Lee LN, Yang PC, Chang DB, Yu CJ, Ko JC, Liaw YS, Wu RG and Luh KT (1994) Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion. Thorax 49: 594–595
Lerner-Tung MB, Chang AYC, Ong LS and Kreiser D (1997) Pharmacokinetics of intrapericardial administration of 5-fluorouracil. Cancer Chemother Pharmacol 40: 318–320
Liu G, Crump M, Gross PE, Dancey J and Shepherd FA (1996) Prospective comparison of the sclerosing agents doxycycline and bleomycin for the primary management of malignant pericardial effusion and cardiac tamponade. J Clin Oncol 14: 3141–3147
Livingston RB, Joseph D, McCracken JD, Trauth CJ and Chen T (1982) Isolated pleural effusion in small cell lung carcinoma: favorable prognosis. Chest 81: 208–211
Lokich J and Anderson N (1998) Carboplatin versus cisplatin in solid tumors: An analysis of the literature. Ann Oncol 9: 13–21
Maher EA, Shepherd FA and Todd TJR (1996) Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 112: 637–643
Okamoto H, Shinkai T, Yamakido M and Saijo N (1993) Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion. Cancer 71: 93–98
Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA and Repta AJ (1978) Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 62: 1359–1362
Pera MF Jr and Harde HCr (1977) Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245–1249
Press OW and Livingston R (1987) Management of malignant pericardial effusion and tamponade. JAMA 257: 1088–1092
Roth JA, Ruckdeschel JC and Weisenburger TH (1989) Comparison of therapy of malignant tumors involving the pericardium. Thoracic Oncol 34: 504–512
Shepherd FA, Morgan C, Evans WK, Ginsberg JF, Watt D and Murphy K (1987) Medical management of malignant pericardial effusion by tetracycline sclerosis. Am J Cardiol 60: 1161–1166
Shinkai T, Tominaga K, Saijo N, Eguchi K, Shimizu E, Shibuya M, Shimabukuro Z, Saito Y, Tsuchiya R and Niitani H (1982) The incidence of cardiac metastasis in primary lung cancer and the management of malignant pericardial effusion. Jpn J Clin Oncol 12: 23–32
Smith FE, Lane M and Hudgins PT (1974) Conservative management of malignant pericardial effusion. Cancer 33: 47–57
Souquet PJ, Chauvin F, Boissel JP, Cellerio R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL and Bernard JP (1993) Polychemotherapy in advanced non small lung cancer: a meta-analysis. Lancet 342: 19–21
Takahashi H, Sasaki Y, Saijo N, Sakurai M, Nakao H, Nakagawa K, Hoshi A, Jett JR and Hong WS (1987) In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemother and Pharmacol 19: 197–200
Takahashi J, Kinomura S, Abe Y, Yoshioka S, Yambe T, Ono S, Ito H, Fukuda H, Yamada K and Sato T (1994) Two cases of malignant effusion treated successfully by loco-regional administration of carboplatin. Jpn J Cancer Chemother 21: 2817–2820
Tomkowski W, Szturmowicz M, Fijalkowska A, Filipecki S and Chojak EF (1994) Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion. J Cancer Res Clin Oncol 120: 434–436
Tomkowski WZ and Filipecki S (1997) Intrapericardial cisplatin for the management of patients with large pericardial effusion in the course of the lung cancer. Lung Cancer 16: 215–222
Vaitkus PT, Hermann HC and LeWinter MM (1994) Treatment of malignant pericardial effusions. JAMA 272: 59–64
van Echo DA, Egorin MJ, Whitacre MY, Olman EA and Aisner J (1984) Phase I clinical and pharmacologic trial of carboplatin for 5 days. Cancer Treat Rep 68: 1103–1114
Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M and Karestes ZL (1990) A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61: 608–611
Yano T, Yokoyama H, Inoue T, Takanashi N, Asoh H and Ichinose Y (1994) A simple technique to manage malignant pericardial effusion with a local instillation of bleomycin in non-small cell carcinoma of lung. Oncology 51: 507–509
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Moriya, T., Takiguchi, Y., Tabeta, H. et al. Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer. Br J Cancer 83, 858–862 (2000). https://doi.org/10.1054/bjoc.2000.1397
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1397
Keywords
This article is cited by
-
Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study
Cancer Chemotherapy and Pharmacology (2019)
-
Pericardial fluid: an underrated molecular library of heart conditions and a potential vehicle for cardiac therapy
Basic Research in Cardiology (2019)
-
A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)
British Journal of Cancer (2009)
-
Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade
Medical Oncology (2008)
-
Akuttherapie onkologischer Notfälle
Intensivmedizin und Notfallmedizin (2007)
